

- 2 Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium. *Mol Psychiatry* 2013; **18**: 497–511.
- 3 Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA *et al.* *Nat Genet* 2011; **43**: 969–976.
- 4 Sklar P, Ripke S, Scott LJ, Andreassen OA, Cichon S, Craddock N *et al.* *Nat Genet* 2011; **43**: 977–983.
- 5 Devlin B, Roeder K. *Biometrics* 1999; **55**: 997–1004.
- 6 Richardson K, Lai CQ, Parnell LD, Lee YC, Ordovas JM. *BMC Genomics* 2011; **12**: 504.
- 7 Gibbs JR, van der Brug MP, Hernandez DG, Traynor BJ, Nalls MA, Lai SL *et al.* *PLoS Genet* 2010; **6**: e1000952.
- 8 1000 Genomes Project Consortium. *Nature* 2010; **467**: 1061–1073.

Supplementary Information accompanies the paper on the Molecular Psychiatry website (<http://www.nature.com/mp>)

## OPEN

# Genes for endosomal NHE6 and NHE9 are misregulated in autism brains

*Molecular Psychiatry* (2014) **19**, 277–279; doi:10.1038/mp.2013.28; published online 19 March 2013

Autism is a highly heterogeneous neurodevelopmental disorder with impaired language, social communication, and restricted and repetitive interests and behavior. Monogenic developmental brain disorders with autism features such as Rett syndrome, Angelman syndrome, Fragile X syndrome, and others provide important tractable models of relevance to severe autism. In addition to observing autism symptoms in the monogenic condition, if the gene responsible is also significantly misregulated in the brains of people with idiopathic autism, then these data provide substantial independent support for the importance of the gene in autism pathophysiology.


Given this logic, we set out to test if there were gene expression changes in postmortem brain tissue from patients with idiopathic autism in the genes of interest that encode the Na<sup>+</sup>/H<sup>+</sup> exchanger family of proteins, with particular interest in the forms of exchangers localized to endosomes, namely, NHE6 and NHE9. Mutations in the X-linked endosomal Na<sup>+</sup>/H<sup>+</sup> Exchanger 6 (*NHE6*, also known as *SLC9A6*) represent a novel neurogenetic syndrome with variable expressivity.<sup>1</sup> In a systematic, large-scale resequencing screen of X-chromosome coding exons in >200 pedigrees consistent with X-linked intellectual disability, *NHE6* was among the top six most recurrently mutated genes.<sup>2</sup> The ‘Christianson syndrome’, based on the initial clinical description, reported an association with autistic symptoms as has been reported subsequently.<sup>3,4</sup> In parallel to the description of autistic symptoms associated with mutations in *NHE6*, Morrow *et al.*<sup>5</sup> published mutations in the highly related endosomal protein *NHE9* in severe autism with epilepsy. Endosomal processes, such as would be suggested by mutations in *NHE6* and *NHE9*, represent an important cellular mechanism for investigations regarding disorders of cognitive development. Interestingly, of the six top

genes implicated in the Tarpey *et al.*<sup>2</sup> study, two of the genes, *NHE6* and *AP1S2*, are known to be involved in endosomal mechanisms.

We therefore investigated whether the expression of *NHE* genes, *NHE6* and *NHE9*, were altered in autism cerebral cortex. We did this by renormalizing and analyzing publically available microarray data. Specifically, we first analyzed data from Voineagu *et al.*,<sup>6</sup> which were previously used to compare autism and control cortex ( $n = 29$  of each). We renormalized the data as described in Voineagu *et al.*,<sup>6</sup> except for when we wished to analyze a subset of *NHE* genes that were excluded from the analysis because of low expression. Among their results, Voineagu *et al.*<sup>6</sup> reported that synapse-associated genes were downregulated in autism cortex,<sup>6</sup> and we confirmed this result by performing differential gene expression analysis<sup>7</sup> between autism and control cortex (for detailed Methods, please see Supplementary Information). We then performed DAVID functional annotation clustering analysis<sup>8,9</sup> on the 197 genes with at least 1.3-fold reduction in autism cortex and  $P < 0.05$  (after Benjamini-Hochberg adjustment<sup>10</sup>), which were the differential expression cutoffs described by Voineagu *et al.*<sup>6</sup> Indeed, the most significant gene set in the top scoring cluster of the DAVID results was the Gene Ontology term ‘synapse,’ for which 21 genes overlapped with those downregulated in autism cortex (BH-adjusted overlap  $P$ -value =  $2.2 \times 10^{-7}$ ). This confirmed that synapse-related genes, such as *GABRA1* and *CHRM1*, were downregulated in autism cortex in the Voineagu *et al.*<sup>6</sup> data set (Supplementary Tables 1 and 2 for description of the downregulated synapse genes). We next tested whether *NHE* genes (*NHE1–11*) were differentially expressed between autism and control cortex using a  $t$ -test (Supplementary Table 3). Notably, *NHE1* and *NHE6* were significantly downregulated in autism cortex ( $P = 0.0030$  and  $0.0042$ , respectively) and *NHE9* was significantly upregulated ( $P = 0.00075$ ), yet other *NHE* genes were not significantly differentially expressed between autism and control cortex ( $P > 0.15$ ).

We further hypothesized that changes in these genes were reflective of broader changes in gene expression, such as downregulation of synapse genes. To investigate the functional changes associated with *NHE1*, *NHE6* and *NHE9* gene expression, we found Pearson correlation coefficients between each of these genes and the average expression of the 21 synapse-related genes. *NHE1* was not significantly correlated with the synapse genes ( $r = 0.15$ ,  $P = 0.28$ ), but *NHE6* and *NHE9* both were strongly correlated with the synapse genes ( $r = 0.86$ ,  $P = 4.2 \times 10^{-18}$  for *NHE6*;  $r = -0.62$ ,  $P = 2.2 \times 10^{-7}$  for *NHE9*—see Figure 1). Furthermore, the sub-population of samples with the lowest *NHE6* expression was almost entirely autism cases, as was the sub-population of high *NHE9* expression. Additionally, *NHE6* and *NHE9* were negatively correlated ( $P = 0.00015$ ), and when *NHE6* expression was high, *NHE9* was tightly regulated. A similar decrease in *NHE9* variability could be seen with high synapse gene expression (Figure 1). Thus, a sub-population within autism is not only associated with lower synapse gene expression, but also with lower *NHE6* expression and increased and potentially misregulated *NHE9* expression. We also studied the correlation of *NHE6* and *NHE9* with the downregulated synapse gene set during normal brain development. We capitalized on the large mRNA-seq data set from human brain made available by the Allen Brain Institute (<http://www.developinghumanbrain.org>). We find that *NHE6* clusters strongly during development with this synapse gene group (see Supplementary Information). *NHE9* expression was far lower embryonically, increased postnatally but did not appreciably cluster with this synapse group in typical brain development (Supplementary Figures 1–3).

We used two independent microarray data sets for autism and control cerebral cortex to validate both the differential gene expression of *NHE6* and *NHE9* in autism cases and these genes’ associations with synapse genes. The validation data sets were



**Figure 1.** Expression plots of *NHE6* versus synapse genes, *NHE9* versus synapse genes and *NHE6* versus *NHE9* in three independent data sets. We compared the average log base 2 expression of 21 synapse genes with that of *NHE6* and *NHE9* expression in microarray data sets published by Voineagu *et al.*<sup>6</sup> (a–c,  $n = 58$ ), Chow *et al.*<sup>11</sup> (d–f,  $n = 33$ ) and Garbett *et al.*<sup>12</sup> (g–i,  $n = 12$ ). Each data set was designed to compare gene expression in autism and control cerebral cortex. The synapse genes used were the 21 synapse genes downregulated in autism cortex compared with control in the Voineagu *et al.*<sup>6</sup> data set (Supplementary Tables 1 and 2).

from Chow *et al.*<sup>11</sup> ( $n = 15$  autism,  $n = 18$  control) and Garbett *et al.*<sup>12</sup> ( $n = 6$  of each; data set details in Supplementary Table 4). The Chow *et al.*<sup>11</sup> data were downloaded from GEO (GSE28475), and the Garbett *et al.*<sup>12</sup> data were provided by the authors. In the Garbett *et al.*<sup>12</sup> data, *NHE9* was significantly higher in autism than control cortex ( $P = 0.039$ ), and while *NHE6* was lower on average in autism cortex, this was not statistically significant ( $P = 0.22$ ), although this may have been due to low sample size (Figure 1). In the Chow *et al.*<sup>11</sup> data, although *NHE6* and *NHE9* had lower and higher expression in autism cortex compared with control, respectively, these trends were not significant ( $P = 0.38$  and  $0.17$ ). However, the mean expression of synapse genes was also not significantly different in the Chow *et al.*<sup>11</sup> data set ( $P = 0.46$ ), suggesting that the Voineagu *et al.*<sup>6</sup> and Chow *et al.*<sup>11</sup> data sets represent different populations. Additionally, *NHE6* and *NHE9* were negatively correlated across data sets, except for in Garbett *et al.*<sup>12</sup> in which the correlation was not significant ( $P = 0.56$ ) but suggesting as yet unknown mechanisms of interaction. Despite this lack of significance in the independent data sets, these genes' associations with synapse genes remained strong in both additional data sets: *NHE6* is positively associated with synapse genes ( $r = 0.59$ ,  $P = 0.00029$  for *NHE6* in Chow *et al.*<sup>11</sup> study; and  $r = 0.6$ ,  $P = 0.041$  for *NHE6* in Garbett *et al.*<sup>12</sup> study—see Figure 1) and *NHE9* negatively associated ( $r = -0.72$ ,  $P = 2.0 \times 10^{-6}$  for *NHE9* in Chow *et al.*<sup>11</sup> study; and  $r = -0.78$ ,  $P = 0.0029$  for *NHE9* in Garbett *et al.*<sup>12</sup> study—see Figure 1). Finally, we tested for an association of gene expression for *NHE6* and *NHE9* and well-established autism-related genes such as *SHANK2/3*, *NLGN4X*, *NRXN1* and *PTEN*. Notably, *NHE6* and *NHE9* each showed a strong association with *NRXN1* ( $P = 2 \times 10^{-10}$  for *NHE6*, and  $P = 2.9 \times 10^{-8}$  for *NHE9*; Supplementary Figures 4 and 5).

In summary, we find interesting gene expression changes in endosomal *NHE6* and *NHE9* in postmortem autism brains. These gene expression changes are largely replicated across data sets or the trends of these changes are maintained given limitations in sample size. We also report a strong correlation of endosomal *NHE6* and *NHE9* gene expression with the synapse genes across all data sets. The strong correlation of endosomal NHEs with synapse genes suggests that changes in synapse genes in autism involves a cellular mechanism that involves endosomal *NHE6* and *NHE9* in at least some autism brains. In conclusion, these gene expression studies in postmortem brains from patients with idiopathic autism provide additional support, in addition to the association of autism symptoms with the single-gene mutations, that endosomal NHEs are mechanistically involved in the pathophysiology of autism.

#### CONFLICT OF INTEREST

The authors declare no conflict of interest.

#### ACKNOWLEDGEMENTS

EMM has received a Career Award in Medical Science from the Burroughs Wellcome Fund and support from NIMH 1K23MH080954-05. This work was supported by a grant from the Simons Foundation (SFARI #239834 to EMM), and also generous support to EMM from the Nancy Lurie Marks Foundation.

M Schwede<sup>1</sup>, K Garbett<sup>2</sup>, K Mirnics<sup>2,3</sup>, DH Geschwind<sup>4,5,6</sup> and EM Morrow<sup>1,7</sup>

<sup>1</sup>Department of Molecular Biology, Cell Biology and Biochemistry, Institute for Brain Science, Brown University, Laboratory for Molecular Medicine, Providence, RI, USA;

<sup>2</sup>Department of Psychiatry, Vanderbilt University, Nashville, TN, USA;  
<sup>3</sup>Vanderbilt Kennedy Center for Research on Human Development,  
 Vanderbilt University, Nashville, TN, USA;  
<sup>4</sup>UCLA Center for Autism Research and Treatment, Semel Institute for  
 Neuroscience and Behavior, Los Angeles, CA, USA;  
<sup>5</sup>Program in Neurogenetics, Department of Neurology, David Geffen  
 School of Medicine at UCLA, Los Angeles, CA, USA;  
<sup>6</sup>Department of Human Genetics, David Geffen School of  
 Medicine at UCLA, Los Angeles, CA, USA and  
<sup>7</sup>Department of Psychiatry and Human Behavior, Emma Pendleton  
 Bradley Hospital, Alpert Medical School of Brown University,  
 East Providence, RI, USA  
 E-mail: eric\_morrow@brown.edu

## REFERENCES

- Gilfillan GD, Selmer KK, Roxrud I, Smith R, Kyllerman M, Eiklid K *et al.* *Am J Hum Genet.* 2008; **82**: 1003–1010.
- Tarpey PS, Smith R, Pleasance E, Whibley A, Edkins S, Hardy C *et al.* *Nat Genet.* 2009; **41**: 535–543.
- Garbern JY, Neumann M, Trojanowski JQ, Lee VM, Feldman G, Norris JW *et al.* *Brain* 2010; **133**(Pt 5): 1391–1402.
- Christianson AL, Stevenson RE, van der Meyden CH, Pelsler J, Theron FW, van Rensburg PL. *J Med Genet.* 1999; **36**: 759–766.
- Morrow EM, Yoo SY, Flavell SW, Kim TK, Lin Y, Hill RS *et al.* *Science* 2008; **321**: 218–223.
- Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S *et al.* *Nature.* 2011; **474**: 380–384.
- Smyth GK. *Stat Appl Genet Mol Biol.* 2004; **3**: Article 3.
- Huang da W, Sherman BT, Lempicki RA. *Nucleic Acids Res.* 2009; **37**: 1–13.
- Huang da W, Sherman BT, Lempicki RA. *Nat Protoc.* 2009; **4**: 44–57.
- Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. *Behav Brain Res.* 2001; **125**: 279–284.
- Chow ML, Pramparo T, Winn ME, Barnes CC, Li HR, Weiss L *et al.* *PLoS Genet.* 2012; **8**: e1002592.
- Garbett K, Ebert PJ, Mitchell A, Lintas C, Manzi B, Mirnics K *et al.* *Neurobiol Dis.* 2008; **30**: 303–311.

 This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/3.0/>

Supplementary Information accompanies the paper on the Molecular Psychiatry website (<http://www.nature.com/mp>)

# Amphetamine-induced behavior requires CaMKII-dependent dopamine transporter phosphorylation

*Molecular Psychiatry* (2014) **19**, 279–281; doi:10.1038/mp.2013.29; published online 19 March 2013

The dopamine (DA) transporter (DAT), which mediates the inactivation of released DA through its reuptake, is a primary molecular target for psychostimulants.<sup>1,2</sup> Cocaine and methylphenidate (MPH) exert their psychostimulant properties by blocking DA reuptake, leading to the elevation of extracellular DA.<sup>2</sup> In contrast, amphetamine (AMPH) acts as a substrate for DAT and subsequently induces non-exocytotic DAT-mediated release of DA (DA efflux).<sup>2</sup> Here we use a *Drosophila* behavioral assay to

delineate the signaling mechanisms that modulate DAT-mediated AMPH-induced behavior *in vivo*. Understanding these mechanisms is critical to understanding how the actions of AMPH might be blocked therapeutically, while simultaneously preserving DA transport.

Multiple lines of evidence suggest that kinase activity can modulate DAT function and, more specifically, AMPH action on DAT. Both calcium/calmodulin kinase II alpha (CaMKII) and protein kinase C (PKC) can phosphorylate an N-terminal DAT peptide *in vitro*<sup>3</sup> and inhibiting the activity of either kinase attenuates AMPH-induced DA efflux in rodent striatal slices.<sup>3,4</sup> Data from CaMKII and PKC knockout mice suggest a role for these kinases in regulating AMPH action *in vivo*.<sup>5,6</sup> However, it is difficult to ascertain from these studies using global knockout strategies whether the observed effects on AMPH-induced DA efflux are mediated directly through alterations in DAT phosphorylation or whether they arise indirectly through phosphorylation of other targets or through circuit effects.

Recently we showed that phosphorylation of the N-terminus of DAT is essential for AMPH-induced, but not MPH-induced hyperlocomotion in *Drosophila*. Larvae respond to either AMPH or MPH by increasing their crawling velocity, and a null mutation in *Drosophila* DAT (*dDAT<sup>fmn</sup>*) abolishes these locomotor responses.<sup>7</sup> Expression of wild-type human (hDAT) in DA neurons of *dDAT<sup>fmn</sup>* mutants rescues the response to either psychostimulant.<sup>7</sup> In contrast, expression of a phospho-deficient mutant hDAT (hDAT-S/A) rescued only the response to MPH but not to AMPH,<sup>7</sup> consistent with studies showing that DAT phosphorylation is required for AMPH-induced DA efflux but not for DA reuptake in heterologous cultured cells.<sup>3,8</sup> Using the tractable *Drosophila* system, we have now determined whether CaMKII is required specifically in DA neurons for AMPH-induced behavior. To inhibit the activity of CaMKII, we used a UAS-driven highly selective inhibitory peptide (CaMKIINtide).<sup>9</sup> We expressed CaMKIINtide in DA neurons of larvae using the tyrosine hydroxylase (TH) GAL4 driver.<sup>10</sup> These larvae were fed either vehicle or AMPH and their speed of locomotion was measured as previously described.<sup>7</sup> Larvae expressing CaMKIINtide in DA neurons (*UAS-CaMKIINtide(2x)/TH-GAL4*) failed to increase their crawling velocity in response to AMPH in contrast to control larvae without TH-Gal4 (*UAS-CaMKIINtide(2x)/+*), which exhibited significant hyperlocomotion (Figure 1a). Expression of CaMKIINtide in DA neurons did not inhibit MPH-induced hyperlocomotion (Figure 1b), consistent with our previous finding that phosphorylation of DAT is not required for the behavioral response to this DA uptake inhibitor.<sup>7</sup> We also found that co-expression of CaMKIINtide with hDAT in DA neurons of mutant larvae that lack dDAT (*dDAT<sup>fmn</sup>; TH-GAL4,UAS-hDAT/UAS-CaMKIINtide(2x)*) blunted AMPH-induced but not MPH-induced hyperlocomotion (Figures 1c and d, respectively). These data show that CaMKII is essential specifically in DA neurons for both dDAT-mediated and hDAT-mediated AMPH-induced hyperlocomotion in *Drosophila*. They also suggest that CaMKII activity is not required for DA uptake *in vivo*, as the response to MPH was unaffected in its absence.

To examine whether the role of CaMKII is mediated via DAT phosphorylation, we determined whether pseudophosphorylation of the DAT N-terminus can decouple the AMPH-induced behavior from the activation state of CaMKII. Previously we demonstrated that a mutant hDAT (hDAT-S/D), which mimics constitutive phosphorylation by mutation of the five N-terminal serines to aspartates, could restore AMPH-induced hyperlocomotion in *dDAT* mutant larvae.<sup>7</sup> When we expressed hDAT-S/D in animals where CaMKII was inhibited (*dDAT<sup>fmn</sup>; TH-GAL4, UAS-hDAT-S/D/UAS-CaMKIINtide(2x)*) we found that the response to AMPH was restored (Figure 1e). In contrast, larvae expressing wild-type hDAT (*dDAT<sup>fmn</sup>; TH-GAL4,UAS-hDAT/UAS-CaMKIINtide(2x)*) failed to respond to AMPH (Figure 1e). These data, combined with *in vitro* studies that show that CaMKII associates with the C-terminus of DAT and phosphorylates an N-terminal DAT peptide,<sup>3</sup> suggest that